HUP0001232A2 - Béta-amiloid peptid kibocsátást és/vagy szintézist gátló cikloalkil-, laktám-, laktonszármazékok, és ezek tio-analógjai, valamint e vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Béta-amiloid peptid kibocsátást és/vagy szintézist gátló cikloalkil-, laktám-, laktonszármazékok, és ezek tio-analógjai, valamint e vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0001232A2 HUP0001232A2 HU0001232A HUP0001232A HUP0001232A2 HU P0001232 A2 HUP0001232 A2 HU P0001232A2 HU 0001232 A HU0001232 A HU 0001232A HU P0001232 A HUP0001232 A HU P0001232A HU P0001232 A2 HUP0001232 A2 HU P0001232A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- cycloalkyl
- substituted
- alkyl
- compounds
- Prior art date
Links
- 125000000753 cycloalkyl group Chemical group 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003951 lactams Chemical class 0.000 title 1
- 150000002596 lactones Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical group 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány tárgyát az (I) általános képletű vegyületek, valamintezeket tartalmazó gyógyászati készítmények képezik. A találmányszerinti vegyületek eredményesen alkalmazhatók a b-amiloid peptidkibocsátásának és/vagy képződésének a sejtekben történő gátlására;ennek következtében eredményesen alkalmazhatók különféle betegségek,így az Alzheimer-kór kezelésére vagy megelőzésére. Az (I) általánosképletben a szubsztituensek jelentése többek között R1 jelentése alkil-, alkenil-, alkinil-, cikloalkil-, cikloalkenil-,szubsz- tituált alkil-, szubsztituált alkenil-, szubsztituáltalkinil-, szubsz- tituált cikloalkil-, szubsztituált cikloalkenil-,aril-, heteroaril- vagy heterociklusos csoport; W többek között a -C(H)pC(=X)- általános képletű csoporttal együttcikloalkil-, cikloalkenil-, heterociklusos, szubsztituált cikloalkil-vagy szubsztituált cikloalkenilcsoport, amely csoportok mindegyikeadott esetben szubsztituálva lehet vagy kondenzálva kettő vagy többgyűrűből álló rendszert képez; X jelentése oxo-, tioxo-, hidroxil-, tiolcsoport vagy hidrogénatom; Y jelentése (a) általános képletű csoport, amelyben R2 jelentésealkil-, alkenil-, alkinil-, cikloalkil-, aril-, heteroaril- vagyheterociklusos csoport, amelyek adott esetben szubsztituensthordozhatnak; Z jelentése -T-CX'X"C(O)-, ahol T jelentése egy kovalens kötés, amelyR1-gyet a -CX'X" csoporthoz köti, oxigénatom, kénatom, -NR5, amelybenR5 jelentése hidrogénatom, acil-, alkil-, aril- vagyheteroarilcsoport; X' jelentése hidrogénatom, hidroxilcsoport vagy fluoratom; X'' jelentése hidrogénatom, hidroxilcsoport vagy fluoratom vagy X' ésegyüttes jelentése egy oxocsoport; m értéke 0 vagy 1; n értéke 0, 1 vagy 2; p értéke 0 vagy 1 bizonyos feltételekhez kötve. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78002596A | 1996-12-23 | 1996-12-23 | |
PCT/US1997/022986 WO1998028268A2 (en) | 1996-12-23 | 1997-12-22 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001232A2 true HUP0001232A2 (hu) | 2000-10-28 |
HUP0001232A3 HUP0001232A3 (en) | 2001-02-28 |
Family
ID=25118329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001232A HUP0001232A3 (en) | 1996-12-23 | 1997-12-22 | Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP0951466B1 (hu) |
JP (1) | JP3812952B2 (hu) |
KR (1) | KR20000069654A (hu) |
CN (2) | CN1616432A (hu) |
AR (1) | AR010854A1 (hu) |
AT (1) | ATE421509T1 (hu) |
AU (1) | AU749658C (hu) |
BR (1) | BR9714517A (hu) |
CA (1) | CA2272305A1 (hu) |
CO (1) | CO4930282A1 (hu) |
DE (1) | DE69739236D1 (hu) |
DK (1) | DK0951466T3 (hu) |
EA (1) | EA002100B1 (hu) |
ES (1) | ES2319239T3 (hu) |
HR (1) | HRP970705A2 (hu) |
HU (1) | HUP0001232A3 (hu) |
ID (1) | ID22177A (hu) |
IL (2) | IL129820A0 (hu) |
NO (1) | NO993098L (hu) |
NZ (1) | NZ335583A (hu) |
PE (1) | PE52799A1 (hu) |
PL (1) | PL196641B1 (hu) |
PT (1) | PT951466E (hu) |
SI (1) | SI0951466T1 (hu) |
TR (1) | TR199901343T2 (hu) |
TW (1) | TW568914B (hu) |
WO (1) | WO1998028268A2 (hu) |
ZA (1) | ZA9711537B (hu) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9812773A (pt) * | 1997-12-22 | 2000-10-10 | Elan Pharm Inc | "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados" |
US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
AU6278099A (en) | 1998-09-30 | 2000-04-17 | Elan Pharmaceuticals, Inc. | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide |
US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2347671A1 (en) | 1998-12-24 | 2000-07-06 | Dupont Pharmaceuticals Company | Succinoylamino benzodiazepines as inhibitors of a.beta. protein production |
AU6071400A (en) | 1999-07-06 | 2001-01-22 | Vertex Pharmaceuticals Incorporated | Cyclized amide derivatives |
WO2001010846A2 (en) * | 1999-08-05 | 2001-02-15 | Igt Pharma Inc. | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
IL147774A0 (en) | 1999-09-13 | 2002-08-14 | Du Pont Pharm Co | Hydroxyalkanoyl aminolactams and related structures as inhibitors of as protein production |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
EP1218377A1 (en) | 1999-10-08 | 2002-07-03 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION |
WO2001034571A1 (en) * | 1999-11-09 | 2001-05-17 | Eli Lilly And Company | β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS |
US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
JP2003528150A (ja) * | 2000-03-28 | 2003-09-24 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Aβタンパク質産生の阻害剤としてのラクタム |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
CN1436175A (zh) | 2000-04-03 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ-蛋白生产抑制剂的环状内酰胺 |
EP1268434A1 (en) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
AU783857B2 (en) | 2000-06-01 | 2005-12-15 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a beta protein production |
US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
GB0025173D0 (en) | 2000-10-13 | 2000-11-29 | Merck Sharp & Dohme | Therapeutic agents |
UA77165C2 (en) * | 2000-11-17 | 2006-11-15 | Lilly Co Eli | (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition |
US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
EP1345955B1 (en) * | 2000-11-17 | 2008-08-20 | Eli Lilly And Company | Lactam dipeptide and its use in inhibiting beta-amyloid peptide release |
UA74849C2 (en) * | 2000-11-17 | 2006-02-15 | Lilly Co Eli | Lactam |
NZ526912A (en) | 2001-01-17 | 2005-02-25 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
EP1362042A1 (en) * | 2001-01-17 | 2003-11-19 | Amura Therapeutics Limited | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
WO2002057270A1 (en) | 2001-01-17 | 2002-07-25 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
FR2840899B1 (fr) * | 2002-06-12 | 2005-02-25 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
CA2505361A1 (en) * | 2002-11-11 | 2004-05-27 | Bayer Healthcare Ag | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist |
DE60335911D1 (de) | 2002-12-20 | 2011-03-10 | Daiichi Sankyo Co Ltd | Isochinolinonderivate und deren verwendung als medikamente |
FR2850380B1 (fr) | 2003-01-23 | 2006-07-07 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
WO2004080983A1 (en) * | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel lactams and uses thereof |
JP2006526015A (ja) | 2003-05-02 | 2006-11-16 | エラン ファーマシューティカルズ,インコーポレイテッド | 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物 |
ITMI20032278A1 (it) | 2003-11-21 | 2005-05-22 | Ethicon Endo Surgery Inc | Dispositivo di diagnosi |
CA2547651C (en) * | 2003-12-01 | 2015-06-23 | Cambridge University Technical Services Limited | Anti-inflammatory agents |
SI1720909T1 (sl) | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
EP1802303B1 (en) | 2004-09-17 | 2011-11-02 | Whitehead Institute For Biomedical Research | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
JP4519621B2 (ja) * | 2004-11-30 | 2010-08-04 | アイバイツ株式会社 | 光酸発生剤および感光性樹脂組成物 |
CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
CN101284828B (zh) * | 2007-04-12 | 2011-04-27 | 中国科学院上海药物研究所 | 环庚烷并吡啶类化合物、其制备方法、用途及包含此类化合物的药物组合物 |
MX2010001754A (es) * | 2007-08-14 | 2010-05-14 | Lilly Co Eli | Derivados de azepina como inhibidores de gamma secretasa. |
PT2222636E (pt) | 2007-12-21 | 2013-07-16 | Ligand Pharm Inc | Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
US10143711B2 (en) | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
AU2010207190A1 (en) * | 2009-01-23 | 2011-08-04 | Msd K.K. | Benzodiazepin-2-on derivatives |
WO2010095766A1 (en) * | 2009-02-17 | 2010-08-26 | Banyu Pharmaceutical Co.,Ltd. | 1,4-benzodiazepin-2-on derivatives |
AR079170A1 (es) | 2009-12-10 | 2011-12-28 | Lilly Co Eli | Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par |
US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
US9403763B2 (en) | 2011-12-14 | 2016-08-02 | Dana-Farber Cancer Institute, Inc. | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
WO2014039781A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
CN103435549A (zh) * | 2013-08-14 | 2013-12-11 | 无锡惠飞生物医药技术有限公司 | 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法 |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
US20170314027A1 (en) | 2014-08-06 | 2017-11-02 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
US9975848B2 (en) | 2014-08-13 | 2018-05-22 | The Trustees Of The University Of Pennsylvania | Inhibitors of HIV-1 entry and methods of use thereof |
WO2016069906A1 (en) | 2014-10-29 | 2016-05-06 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
CA3013038A1 (en) | 2016-01-29 | 2017-08-03 | Massachusetts Eye And Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
CN109310684B (zh) | 2016-04-12 | 2021-11-19 | 伊莱利利公司 | 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法 |
AU2017249988C1 (en) | 2016-04-12 | 2023-02-16 | Eli Lilly And Company | Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer |
EP3458076A4 (en) | 2016-05-16 | 2020-01-22 | The General Hospital Corporation | HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL |
IL263110B (en) | 2016-05-20 | 2022-07-01 | Lilly Co Eli | Combined treatment of notch and pd-1 or pd-l1 inhibitors |
CN106243050B (zh) * | 2016-08-10 | 2019-09-06 | 安徽恒星制药有限公司 | 一种适合工业化生产氯巴占的方法 |
WO2018071307A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
EP3582782B1 (en) | 2017-02-17 | 2023-06-07 | Fred Hutchinson Cancer Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
EP3743057A4 (en) | 2018-01-26 | 2021-11-17 | Massachusetts Eye & Ear Infirmary | TREATMENT OF HEARING LOSS |
CN113754616B (zh) * | 2021-09-27 | 2023-07-18 | 北京工商大学 | 一种反式-3-苯硫基-γ-内酯的制备方法 |
CN116116396B (zh) * | 2023-02-20 | 2023-11-14 | 哈尔滨工程大学 | 一种偕胺肟基凝胶/氧化石墨/海绵复合材料的制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE42215B1 (en) * | 1973-12-28 | 1980-07-02 | Fujisawa Pharmaceutical Co | Azetidinone derivatives and process for preparation thereof |
FR2278335A1 (fr) * | 1974-07-04 | 1976-02-13 | Fujisawa Pharmaceutical Co | Derives d'azetidinones et leurs procedes de preparation |
NZ264143A (en) * | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5849691A (en) * | 1996-02-20 | 1998-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II |
-
1997
- 1997-12-22 IL IL12982097A patent/IL129820A0/xx unknown
- 1997-12-22 ID IDW990563A patent/ID22177A/id unknown
- 1997-12-22 HR HR08/780,025A patent/HRP970705A2/hr not_active Application Discontinuation
- 1997-12-22 CN CNA2004100578889A patent/CN1616432A/zh active Pending
- 1997-12-22 WO PCT/US1997/022986 patent/WO1998028268A2/en not_active Application Discontinuation
- 1997-12-22 HU HU0001232A patent/HUP0001232A3/hu unknown
- 1997-12-22 AU AU57007/98A patent/AU749658C/en not_active Ceased
- 1997-12-22 EP EP97953208A patent/EP0951466B1/en not_active Expired - Lifetime
- 1997-12-22 CN CNB971809011A patent/CN1171878C/zh not_active Expired - Fee Related
- 1997-12-22 IL IL15835597A patent/IL158355A0/xx unknown
- 1997-12-22 PT PT97953208T patent/PT951466E/pt unknown
- 1997-12-22 SI SI9730787T patent/SI0951466T1/sl unknown
- 1997-12-22 BR BR9714517-3A patent/BR9714517A/pt not_active IP Right Cessation
- 1997-12-22 NZ NZ335583A patent/NZ335583A/en unknown
- 1997-12-22 CA CA002272305A patent/CA2272305A1/en not_active Abandoned
- 1997-12-22 KR KR1019997005677A patent/KR20000069654A/ko not_active Application Discontinuation
- 1997-12-22 AT AT97953208T patent/ATE421509T1/de active
- 1997-12-22 TR TR1999/01343T patent/TR199901343T2/xx unknown
- 1997-12-22 DE DE69739236T patent/DE69739236D1/de not_active Expired - Lifetime
- 1997-12-22 DK DK97953208T patent/DK0951466T3/da active
- 1997-12-22 EA EA199900593A patent/EA002100B1/ru not_active IP Right Cessation
- 1997-12-22 ES ES97953208T patent/ES2319239T3/es not_active Expired - Lifetime
- 1997-12-22 JP JP52886798A patent/JP3812952B2/ja not_active Expired - Fee Related
- 1997-12-22 ZA ZA9711537A patent/ZA9711537B/xx unknown
- 1997-12-22 PL PL334305A patent/PL196641B1/pl unknown
- 1997-12-23 PE PE1997001158A patent/PE52799A1/es not_active Application Discontinuation
- 1997-12-23 CO CO97074775A patent/CO4930282A1/es unknown
- 1997-12-23 AR ARP970106159A patent/AR010854A1/es unknown
- 1997-12-23 TW TW086119638A patent/TW568914B/zh not_active IP Right Cessation
-
1999
- 1999-06-22 NO NO993098A patent/NO993098L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001232A2 (hu) | Béta-amiloid peptid kibocsátást és/vagy szintézist gátló cikloalkil-, laktám-, laktonszármazékok, és ezek tio-analógjai, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
HUP0100270A2 (hu) | Eljárások és vegyületek béta-amiloid peptid kibocsátás és/vagy szintézisgátló peptidek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0202469A2 (hu) | Sejt adhéziós inhibitor vegyület és ilyet tartalmazó gyógyszerkészítmény | |
HUP0004259A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények | |
HUP0204083A2 (hu) | 2-Amino-nikotin-amid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és VEGF receptor tirozin kináz inhibitorként való alkalmazásuk | |
HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
AR005999A1 (es) | Nuevos derivados de eritromicina, su procedimiento de preparacion, composiciones farmaceuticas y medicamentos | |
HUP0004531A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
ES8206491A1 (es) | Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina. | |
HUP0000567A2 (hu) | Szulfonil-karbamid-származékok és ezeket tartalmazó interleukin-1 aktivitás gátlására szolgáló gyógyászati készítmények | |
DK387889D0 (da) | Makrolider, og farmaceutiske praeparater med indhold af saadanne forbindelser | |
DE60004217D1 (de) | Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon | |
HUP9903815A1 (hu) | Szubsztituált purin-vázas vegyületek, ezeket tartalmazó gyógyszerkészítmények, intermedierek | |
HUP0100669A2 (hu) | Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
HUP0202876A2 (hu) | Karboxipeptidáz U gátló új vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0001164A2 (hu) | PF1022-ciklodepszipeptid-származékok | |
NO944946D0 (no) | Forgrenet-amino-substituerte tiazoler, fremgangsmåter for fremstilling av dem og farmasöytiske blandinger inneholdende dem | |
HUP0002442A2 (hu) | Heterociklusos tio-észterek nitrogénen át kapcsolódó karbamid- és karbamátszármazékai, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
ATE161717T1 (de) | Antivirale mittel | |
HUP0004793A2 (hu) | Eljárás alatrofloxacin-mezilát tisztítására és alkalmazására, a vegyületet tartalmazó parenterális készítmények | |
EP0202654A3 (en) | 5-carboxy-1,4-dihydropyrimidine derivatives | |
HUP9901376A2 (hu) | 1-Metil-karbapenem-származékok, alkalmazásuk, előállításuk, ezeket tartalmazó gyógyszerkészítmények | |
HUP0402341A2 (hu) | Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére | |
HUP9802042A2 (hu) | Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
DE69837334D1 (de) | Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |